Status:

COMPLETED

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Lead Sponsor:

GlaxoSmithKline

Conditions:

Pulmonary Disease, Chronic Obstructive

Eligibility:

All Genders

50+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with ri...

Detailed Description

This is a multicenter, randomized, double-blind, placebo controlled study to evaluate the effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC) BID on arterial stiffness in COPD subjects....

Eligibility Criteria

Inclusion

  • Signed and dated written informed consent obtained from the subject and/or subject's legally acceptable representative prior to study participation.
  • Males or females greater then or equal to 50 years of age.
  • A post-albuterol FEV1/FVC ratio of \< or equal to 0.70
  • A post-albuterol FEV1 \< 80% of predicted normal.
  • Patients can be current or fomer smoker and must have a cigarette smoking history of \> greater then or equal to 10 pack-years .

Exclusion

  • A current diagnosis of asthma
  • A body mass index (BMI) of \> or equal to 35kg/m2
  • A respiratory diagnosis other than COPD (e.g., lung cancer, bronchiectasis, sarcoidosis, tuberculosis, lung fibrosis).

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

249 Patients enrolled

Trial Details

Trial ID

NCT00857766

Start Date

March 1 2009

End Date

March 1 2010

Last Update

January 30 2017

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

GSK Investigational Site

Birmingham, Alabama, United States, 35294

2

GSK Investigational Site

Jasper, Alabama, United States, 35501

3

GSK Investigational Site

Mobile, Alabama, United States, 36608

4

GSK Investigational Site

Phoenix, Arizona, United States, 85006